Skip to main content
. 2019 Nov 7;12:9435–9447. doi: 10.2147/OTT.S222881

Figure 6.

Figure 6

U0126 partially diminishes the effects of GOF-SHP2 on glioblastoma cells. (A and B) WT-SHP2 and MT-SHP2 U87 and A172 cells were treated with U0126 (10 μmol/l) or DMSO for 24 h. Western blotting analysis was used to measure the levels of p-ERK, ERK, p-CREB, and CREB. β-actin was used as a loading control. (C and D) The MTT assay was employed to test the viability of glioblastoma cells in the WT-SHP2 and MT-SHP2 groups in the presence of U0126 or DMSO. (E and F) The cloning experiment was used to test the proliferation ability of cells. The WT-SHP2 and MT-SHP2 groups were treated with U0126 or DMSO twice per week for 2 weeks. (G and H) The migration ability of cells was measured using the Transwell chamber assay in the presence of U0126 or DMSO. The data are presented as the means ± SEM (*P<0.05 and ***P<0.001).

Abbreviations: GOF, gain-of-function; CREB, cAMP-response element-binding protein; ERK, extracellular signal-regulated kinase; SHP2, Src homology-2 domain-containing protein-tyrosine phosphatase-2; WT, wild type; MT, mutant; DMSO, dimethyl sulphoxide; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide.